A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension

NCT00922441 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: Fimasartan 60 mg group
DRUG: Fimasartan 120 mg group
DRUG: Reference (Valsartan 80 mg) group

Sponsor

Boryung Pharmaceutical Co., Ltd

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]